Pharming Group NV (PHAR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.78 (+1.70%), Market cap $0.91B, P/E ratio 67.68, 52-week low–high $9.31 ~ $21.18.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was
Financial statements, price targets, institutional (13F) holdings and related news for Pharming Group NV are updated in real time on BlackAll Trade.
Pharming Group NV trades at $10.78 (+1.70%). Real-time quotes and charts are available on BlackAll Trade.
Pharming Group NV has a market cap of about $0.91B. Its P/E ratio is 67.68.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and